文献速递胸部肿瘤放疗

等毒性调强放疗在III期非小细胞肺癌中的可行性研究

Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-11-21

这项多中心可行性研究纳入37例不适合同步放化疗的III期非小细胞肺癌患者,采用等毒性调强放疗结合超分割、加速和剂量递增策略,在放疗前至少接受2周期铂类化疗。中位处方肿瘤剂量为77.4 Gy,14例达到79.2 Gy最大剂量,仅2例未能达到EQD2>60 Gy,中位生存18.1个月,2年总生存率33.6%,表明该方案耐受良好且可行。

要点

  • 等毒性IMRT在III期NSCLC中可行,中位剂量77.4 Gy,仅5.4%未达EQD2>60 Gy。
  • 3级食管炎2例,无3-4级肺炎,但发生3例5级事件。
  • 中位生存18.1个月,2年总生存率33.6%。

核心结论

  • 等毒性IMRT是耐受良好且可行的治疗强化方法,适用于不适合同步放化疗的III期NSCLC患者。

研究设计与样本

  • 多中心可行性研究,纳入37例不可切除III期NSCLC、ECOG PS 0-2且不适合同步放化疗的患者,来自7个英国中心。
  • 放疗前强制至少2周期铂类化疗,采用1.8 Gy每日两次分割,实施放疗质量保证计划。

主要发现

  • 37例中2例(5.4%)未能达到EQD2>60 Gy,中位处方肿瘤剂量77.4 Gy(范围61.2-79.2 Gy),14例(37.8%)达到最大剂量79.2 Gy。
  • 3级食管炎2例,无3-4级肺炎,发生3例5级事件:急性放射性肺炎、支气管肺出血和急性肺部感染。
  • 中位随访25.4个月(范围8.0-44.2个月,基于35例存活者中的11例),中位生存18.1个月(95%CI 13.9-30.6),2年总生存率33.6%(95%CI 17.9-50.1),无进展生存率23.9%(95%CI 11.3-39.1)。

关键数值与推荐

  • 主要目标为递送等毒性IMRT至剂量>60 Gy EQD2(假设α/β比值为10 Gy)。
  • 放疗剂量递增至最大79.2 Gy或任一危及器官达到预设约束。

临床怎么用

  • 对于不适合同步放化疗的III期NSCLC患者,可考虑等毒性IMRT作为治疗强化策略,需注意5级不良事件风险。

局限性

  • 本研究为可行性研究,样本量较小(37例),缺乏对照臂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Not all patients with stage III non-small cell lung cancer (NSCLC) are suitable for concurrent chemoradiation therapy (CRT). Local failure rate is high for sequential concurrent CRT. As such, there is a rationale for treatment intensification. METHODS AND MATERIALS: Isotoxic intensity modulated radiation therapy (IMRT) is a multicenter feasibility study that combines different intensification strategies including hyperfractionation, acceleration, and dose escalation facilitated by IMRT. Patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, and unsuitable for concurrent CRT were recruited. A minimum of 2 cycles of platinum-based chemotherapy was compulsory before starting radiation therapy (RT). Radiation dose was increased until a maximum dose of 79.2 Gy was reached or 1 or more of the organs at risk met predefined constraints. RT was delivered in 1.8-Gy fractions twice daily, and an RT quality assurance program was implemented. The primary objective was the delivery of isotoxic IMRT to a dose >60 Gy equivalent dose in 2-Gy fractions (EQD2 assuming an α/β ratio of 10 Gy for acute reacting tissues). RESULTS: Thirty-seven patients were recruited from 7 UK centers. Median age was 69.9 years (range, 46-86 years). The male-to-female ratio was 17:18. ECOG PS was 0 to 5 in 14.2% of patients; PS was 1 to 27 in 77.1% of patients; PS was 2 to 3 in 8.6% of patients. Stage IIIA:IIIB ratio was 22:13 (62.9%:37.1%). Of 37 patients, 2 (5.4%) failed to achieve EQD2 > 60 Gy. Median prescribed tumor dose was 77.4 Gy (range, 61.2-79.2 Gy). A maximum dose of 79.2Gy was achieved in 14 patients (37.8%). Grade 3 esophagitis was reported in 2 patients, and no patients developed grade 3 to 4 pneumonitis. There were 3 grade 5 events: acute radiation pneumonitis, bronchopulmonary hemorrhage, and acute lung infection. Median follow-up at time of analysis was 25.4 months (range, 8.0-44.2) months for 11 of 35 survivors. The median survival was 18.1 months (95% confidence interval [CI], 13.9-30.6), 2-year overall survival was 33.6% (95% CI, 17.9-50.1), and progression-free survival was 23.9% (95% CI, 11.3-39.1). CONCLUSIONS: Isotoxic IMRT is a well-tolerated and feasible approach to treatment intensification.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Haslett K, Bayman N, Franks K, et al. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 33232772. doi:10.1016/j.ijrobp.2020.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。